Gilead's New Hep B Treatment Shows Safety Benefit But Is It Enough?
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. is to file for US and EU approval this quarter of its once-daily treatment for hepatitis B, tenofovir alafenamide (TAF) 25 mg, on the basis of two newly reported Phase III studies.